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Simple Summary: Shear wave elastography is an ultrasound-based imaging modality that can
delineate prostate lesions that are stiffer, possibly due to cancerous changes. Using evidence from
16 published studies, including more than 2200 patients with suspected or biopsy-proven prostate
cancer, we showed that shear wave elastography has good sensitivity and specificity for the detection
of prostate cancer.
Abstract: Background: ultrasound-based shear wave elastography (SWE) can non-invasively assess
prostate tissue stiffness. This systematic review aims to evaluate SWE for the detection of prostate
cancer (PCa) and compare diagnostic estimates between studies reporting the detection of all PCa and
clinically significant PCa (csPCa). Methods: a literature search was performed using the MEDLINE,
EMBASE, Cochrane Library, ClinicalTrials.gov, and CINAHL databases. Studies evaluating SWE for
the detection of PCa using histopathology as reference standard were included. Results: 16 studies
including 2277 patients were included for review. Nine studies evaluated SWE for the detection of
PCa using systematic biopsy as a reference standard at the per-sample level, with a pooled sensitivity
and specificity of 0.85 (95% CI = 0.74–0.92) and 0.85 (95% CI = 0.75–0.91), respectively. Five studies
evaluated SWE for the detection of PCa using histopathology of radical prostatectomy (RP) specimens
as the reference standard, with a pooled sensitivity and specificity of 0.71 (95% CI = 0.55–0.83) and
0.74 (95% CI = 0.42–0.92), respectively. Sub-group analysis revealed a higher pooled sensitivity (0.77
vs. 0.62) and specificity (0.84 vs. 0.53) for detection of csPCa compared to all PCa among studies
using RP specimens as the reference standard. Conclusion: SWE is an attractive imaging modality
for the detection of PCa.
Keywords: prostate cancer; shear wave elastography; ultrasound
1. Introduction
Traditionally the diagnosis of PCa has involved interpreting serum prostate-specific
antigen (PSA) levels, with or without the results of a digital rectal examination (DRE) to
guide the need for transrectal, ultrasound-guided systematic biopsies (SBs). This diagnostic
pathway is limited by PSAs’ poor specificity and sampling error with SBs, resulting in
the overdiagnosis of clinically insignificant (low-grade) PCa and the underdiagnosis of
clinically significant (high-grade) PCa (csPCa) [1,2]. Consequentially, men with indolent
PCa underwent unnecessary treatment incurring the risk of treatment-related side-effects
and costs to the health care system [3].
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To address these limitations, multiparametric MRI (mpMRI) is currently recommended
by the European Association of Urology (EAU) as the first line of investigation and for
guiding biopsy in men with clinically suspected, localised PCa [4]. However, due to
factors, including variable inter-reader agreement and poor reproducibility of MRI targeted
biopsy procedures, its sensitivity for detecting csPCa outside large-volume centres remains
unclear [5,6]. Hence, SBs continue to play an important role in the diagnosis of PCa. As
conventional B-mode and Doppler ultrasound suffer from limited diagnostic accuracy and
poor lesion conspicuity, an unpleasant systematic sampling approach becomes necessary [7].
For this purpose, transrectal shear wave elastography (SWE) has been evaluated for the
detection of PCa.
SWE renders a parametric image of tissue stiffness (Young modulus) estimates by
computing shear-wave speed throughout target tissues. Stiffer malignant tissue can be
distinguished from the benign regions of the prostate gland in real time using SWE, without
the need for manual compression [8]. SWE has been evaluated for the detection of PCa
with variable results for diagnostic accuracy. In particular, stiff benign prostatic nodules in
the central gland can affect the accuracy of SWE. As the accepted standard of care shifts
towards mpMRI, the combination approach of mpMRI with SWE may be of value, with
preliminary reports showing improved sensitivity for the detection of csPCa [9,10].
With increasing focus on detecting csPCa, newer studies evaluating SWE for the
detection of PCa have adopted stricter histopathological definitions for PCa, which have
yet to be considered in existing reviews [11–13]. Thus, in this systematic review we aim to
do the following:
1. Evaluate detection rates of PCa with SWE, with respect to the reference standard
used (i.e., SB level and whole-mount histopathology of the radical prostatectomy (RP)
specimen);
2. Compare diagnostic estimates between studies reporting detection of all PCa with
studies reporting detection of csPCa (defined as having at least a Gleason score >6
with a tumour burden ≥3 mm).
2. Results
From the electronic literature search, 251 articles were identified. After exclusion
of 103 duplicate articles, the remaining 148 articles were screened, and 27 articles were
deemed suitable for full-text assessment. Of these, 16 articles were included for quantitative
analysis (Figure 1) [9,10,14–27]. Full-text articles were excluded for the following reasons:
observer inter/intra reliability studies (n = 2) [28,29], included overlapping participants
(n = 3) [30–32], involved alternative elastography technique (n = 1) [33], included patients
with radioresistant prostate cancer (n = 1) [34], or had insufficient diagnostic performance
data to reconstruct 2 × 2 tables (n = 4) [35–38].
The patient and SWE investigation characteristics of studies included in this review
are summarized in Tables 1 and 2, respectively. Most studies (8/16) originated from Europe,
with one and seven studies from the United States and Asia, respectively. The patient
population in the individual studies ranged between 10–489 patients. The mean age of
patients in whom SWE was performed ranged between 61.5–71.3 years. The mean PSA
and prostate volume ranged between 5.0–18.2 ng/mL and 32.6–66.9 mL, respectively.
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Table 1. Patient demographic overview of studies included in this review. Study by Rouviere has been stratified as Rouviere
a and Rouviere b to represent results from SWE performed on axial and sagittal planes, respectively. Only the results from
the latter study with better diagnostic estimates were included for analysis. SB: systematic biopsy; PSA: prostate-specific
antigen; PCa: prostate cancer; SWE: shear wave elastography; BPH: Benign Prostatic Hyperplasia; NS: Not stated; TRUS:
Trans-rectal ultrasound; DRE: Digital rectal exam; CEUS: Contrast enhanced ultrasound; RP: Radical prostatectomy.
First Author Country Year Design n n with PCa Inclusion Criteria
Mean
Pathology
Reference
Definition of
PCaAge PSA (ng/mL) ProstateVolume (mL)
Zheng [14] China 2012 Retrosp 107 NS
Planned SB (biopsy indication: BPH and PSA >
4 ng/mL, as well as abnormal DRE and abnormal
findings on TRUS)
66.7 NS NS SB Not specified
Barr [15] United States 2012 Prosp 53 11 Planned SB (biopsy indication: PSA > 4 ng/mLand/or abnormal DRE). 64.2 5.05 NS SB Not specified
Ahmad a [21] United
Kingdom 2013
Prosp
39 22 Planned prostate biopsy (PSA > 4 ng/mL,
abnormal DRE, on active surveillance, and/or
previous abnormal prostate biopsy).
69
>20
NS
-SWE-targeted
biopsy
-SB
Gleason score
of 6 or greater.Ahmad b [21] 11 11 4–20
Woo [16] Korea 2014 Retrosp 87 26 Planned SB (biopsy indication: PSA > 4 ng/mLand/or abnormal DRE). 66.0 12.8 58.6 SB Not specified
Boehm a [17] Germany 2015 Prosp 28 28 Planned open or robotic assisted RP followingbiopsy proven PCa. NS 8.6 (median) NS
Whole-mount
RP
histopathol-
ogy
Gleason score
of 6 or greater.
Boehm b [18] Germany 2015 Prosp 95 38
Planned prostate biopsy (PSA > 4 ng/mL and/or
abnormal DRE and no history of prostate cancer
or TURP).
67
(me-
dian)
6.7 (median) 50.0 (median)
-SWE-
targeted
biopsy
-SB
Gleason
pattern 4 or
greater with
more than
two affected
cores.
Correas [19] France,United STates 2015 Prosp 184 68
Planned SB (PSA > 4.0 ng/mL or increasing PSA
and/or abnormal DRE). 65.1 7.46 52.0 SB
Gleason score
of 6 or greater
and at least 3
mm.
Zhang a [22] China 2015 Retrosp 489 221 Suspected PCa undergoing prostate biopsy 70.21 14.52 NS
-SB
-SWE
combined
with
transition
zone biopsy
Not specified
Rouviere a
[20] France 2016 Prosp 30 30 Planned RP
63
(me-
dian)
6.5 (median) 42 (median)
Whole mount
RP
histopathol-
ogy
Gleason score
of 5 or greater.
Rouviere b
[20]
Prosch a [23]
Germany 2016 Prosp 10 10
Patients who received SWE investigation and
treated with RP based on TRUS guided biopsy
results.
61.5 7.2 32.6
SB
Gleason score
of 6 or greater.
Prosch b [23]
Whole-mount
RP
histopathol-
ogy
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Table 1. Cont.
First Author Country Year Design n n with PCa Inclusion Criteria
Mean
Pathology
Reference
Definition of
PCaAge PSA (ng/mL) ProstateVolume (mL)
Wei [24] UnitedKingdom 2018 Prosp 212 212
Confirmed PCa on SB and imaging (≤cT2) and
scheduled for LRP. 67.6 11.8 66.9
Whole-mount
RP
histopathol-
ogy
Gleason score
greater than 6
and cancer
burden
greater than 5
mm.
Mannaerts
[25]
Netherlands,
Germany 2019 Prosp 48 48
PCa proven on biopsy with PSA ≤ 20 ng/mL and
no extracapsular disease on DRE. Men who
underwent PCa therapy or have contraindication
to CEUS were excluded.
65
(me-
dian)
7.7
(median)
40.0
(median)
Whole-mount
RP
histopathol-
ogy
Gleason score
of 7 or greater
and at least
0.5 ml tumour
volume.
Xiang [9] China 2019 Retrosp 367 135
Patients who underwent transperineal prostate
biopsy (PSA > 10 ng/mL, increasing PSA levels
by 0.75 ng/mL/year, or abnormal DRE). Excluded
if they did not undergo MRI or SWE, or if PSA >
100 ng/mL
66.9 16.1 44.6 SB Gleason scoreof 7 or greater.
Zhang b [10] China 2019 Prosp 78 38
Planned SB (PSA > 4 ng/mL or increasing PSA
levels by 0.50 ng/mL/year, and interval between
prostate biopsy and TRUS and MRI examination <
1 week). Malignant PCa group included only
stage 2a or lower based on histopathology.
66.3 18.2 52.4 -SB Gleason scoreof 6 or greater.
Ji [26] China 2019 Prosp 215 113
Patients with abnormal PSA, a nodule palpated
on DRE, or one or more nodules on TRUS and
MRI. Excluded if have a history of prostate
biopsy/surgery or received endocrine therapy.
71.3 NS NS SB Not specified
Fu [27] China 2020 Prosp 221 85
Patients with elevated serum PSA level
(>4 ng/mL), palpable
nodular lesion in DRE, abnormal TRUS, or
MRI finding.
68.8 5.0 52.4
-SWE-
targeted
biopsy
-SB
Gleason score
of 7 or greater
and/or %
cancer greater
than 50%
Table 2. SWE characteristics of studies included in this review. QAB: quantitative analysis box; NS: Not stated; PZ:
Peripheral zone; Y: yes.
First Author Year
SWE
Ultrasound
System
Plane of Scan QAB Size (mm) SWE FocusRegion
No. of SWE
Read-
ings/Patient
Total SWE
Readings Blinded
SWE Cut-Off
Value (kPa) Analyses Performed
Zheng [14] 2012 Acuson S2000 NS 10 × 5 Whole prostate NS 209 Y 2.5 m/s Sample level
Barr [15] 2012 Aixplorer Axial andtransverse 6 PZ 6 318 Y 37.0 Sample level
Ahmad a [21]
2013 Aixplorer
Axial and
Sagittal NS Whole prostate 12
485
Y NS Sample level
Ahmad b [21] 141
Woo [16] 2014 Aixplorer Axial andSagittal 5 Whole prostate 12 1058 Y 43.9 Sample level
Correas [19] 2015 Aixplorer Transverse 3–7 PZ 12 1040 Y 35.0 Sample and participant level
Boehm a [17] 2015 Aixplorer NS NS Whole prostate 12 322 Y 50.0 Sample level
Zhang a [22] 2015 Aixplorer NS NS Whole prostate NS NS Y 28.5 Sample level
Boehm b [18] 2015 Aixplorer NS NS PZ NS NS Y 50.0 Participant level
Rouviere a [20]
2016 Aixplorer
Axial
NS PZ NS
251
Y
45.0
Sample level
Rouviere b [20] Sagittal 52 52.0
Prosch a [23]
2016 Aixplorer Transverse NS Whole prostate 12 120 NS 50.0 Sample level
Prosch b [23]
Wei [24] 2018 Aixplorer Axial andSagittal 4–6 Whole prostate 12 2544 Y 82.6 Sample level
Mannaerts [25] 2019 Aixplorer Transverse NS Whole prostate 12 576 Y 50.0 Sample level
Xiang [9] 2019 Aixplorer Transverse 3–5 PZ 6 NS Y 40.8 Sample level
Zhang b [10] 2019 Aixplorer Transverse NS Whole prostate NS NS Y NS Participant level
Ji [26] 2019 Aixplorer Transverse NS Whole prostate 6 NS Y 62.3 Participant level
Fu [27] 2020 Aixplorer NS 3–7 Whole prostate 6 2749 Y 42.0 Sample and participant level
All 16 studies included in this review were published between 2011 and 2020. In 11
studies, SB was used as a reference standard to evaluate the diagnostic accuracy of SWE
for prostate cancer. Four studies utilized whole-mount histopathology of RP specimens
as a reference standard. One study evaluated the diagnostic accuracy of SWE with both
above-mentioned reference standards. Thirteen studies reported data on the diagnostic
accuracy of SWE at the per-sample level (i.e., core, sextant level), whereas the remaining
studies reported at a per-patient level.
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Five studies utilised a histopathological threshold of at least a Gleason score greater
than 6, and were hence classified as evaluating SWE for the detection of csPCa. Of these,
three studies had been published since 2019.
Eleven studies performed SWE in patients who had suspected prostate cancer whereas,
five studies only included patients with a confirmed diagnosis of prostate cancer. To
measure prostate stiffness, the majority of studies used the Aixplorer SWE imaging system
(SuperSonic Imagine, Aux-en-Provence, France), whereas one study utilized the Accuson
S2000 Virtual touch quantification system (Siemens Healthineers, Mountain view, CA,
United States). For the studies using the Aixplorer SWE imaging system, which displays
an elasticity image and allows a choice of imaged quantity, either shear-wave speed
(m/s) or Young’s modulus (kPa), the reported quantitative analysis-box (QAB) dimension
ranged between 3–7 mm. For the study using the latter system, only the measurement
of shear-wave speed (m/s) is possible. The equivalent of this QAB is a rectangle of fixed
size, approximately 10 mm × 6 mm, across which the shear-wave speed is measured.
Twelve studies performed SWE targeting the whole prostate gland or the peripheral zone
(PZ) in addition to the transitional zone (TZ), whereas the PZ only was assessed in four
studies. Among studies using the Aixplorer SWE system, cut-off values for distinguishing
malignant from benign prostatic lesions ranged from 28.5 to 82.6 kPa. One study using
Virtual Touch quantification used a cut-off value of 2.5 m/s.
There was considerable variation in the methodological quality of the studies included
in this review (Figure 2). Four studies were deemed to have a high risk of bias in patient
selection, due to their retrospective or case-control design [9,14,16,22]. For the index test
(SWE for the detection of PCa), the risk of bias was high in four studies with inadequate
information regarding SWE cut-off values as well as the total number of SWE images
acquired at per-sample level analysis performed, which was not reported [9,10,21,22].
Information regarding whether pathologists interpreting the reference standard were
blinded to the SWE results was not reported in one study, resulting in an unclear risk of
bias in the index test [23]. Among the studies that used whole-mount RP specimens as
reference standards, two studies did not report the duration between the SWE investigation
and RP, resulting in an unclear risk of bias for flow and timing [17,23]. One study was
deemed to have a high risk of bias in this category, as an additional reference standard
was used in a small group of patients who underwent RP [15]. There was high concern
about the applicability of patient selection amongst studies that enrolled patients with an
established diagnosis of PCa [17,20,24,25]. For the applicability of the index test, there was
high concern in one study, as the stiffness estimate was derived from two QABs along
the predicted biopsy tract [16]. In this category, the concern was unclear in one study,
which evaluated SWE estimates in conjunction with contrast-enhanced ultrasound (CEUS)
findings using a Likert scale [25].
Nine studies, including a total of 1568 patients, evaluated SWE at the per-sample
level for the diagnosis of prostate cancer, with histopathology of SB as the reference
standard. The sensitivities and specificities of individual studies ranged from 0.43 (95%
CI = 0.32–0.55) to 0.96 (95% = CI 0.80–1.00) and 0.43 (95% CI = 0.31–0.56) to 0.96 (95%
CI = 0.93–0.98), respectively. An inverse relationship between sensitivity and specificity
would be expected if the decision threshold were the only source of variation between
studies. Such a threshold effect was not observed, whether on visual interpretation of the
forest plot (Figure 3a) or hierarchical summary receiver operating characteristic (HSROC)
plot (Figure 3c), or by assessment of the Spearman correlation coefficient between sensitivity
and false positive rate (−0.584; p = 0.08). The pooled per-sample sensitivity and specificity
of SWE for the diagnosis of prostate cancer, with histopathology of core biopsy specimens
as the reference standard, were 0.85 (95% CI = 0.74–0.92) and 0.85 (95% CI = 0.75–0.91),
respectively (HSROC shown in Figure 3c (blue plot); area under curve (AUC) = 0.913).
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Figure 2. Methodological quality assessment, with respect to risk of bias and applicability concerns,
of the included studies, according to the revised Quality Assessment of Diagnostic Accuracy Studies
(QUADAS-2) tool.
Five studies reported adequate per-patient level data evaluating SWE for the diagnosis
of prostate cancer with the histopathology of SB specimens as a reference standard [5,9].
Overall, these studies included 793 participants, of which 342 (43.1%) had biopsy-positive
prostate cancer. A weak threshold effect was observed upon visual interpretation of forest
plot (Figure 3b) and HSROC plot (Figure 3c), as well as assessment of the Spearman
correlation coefficient between sensitivity and false positive rate (0.821, p = 0.09). The
sensitivities and specificities of individual studies ranged from 0.78 (95% CI = 0.69–0.86)
to 0.95 (95% CI = 0.82–0.99), and 0.33 (95% CI = 0.21–0.47) to 0.83 (95% CI = 0.68–0.93),
respectively (Figure 3b). The pooled sensitivity and specificity of SWE for the diagnosis
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of prostate cancer at the per-patient level was 0.87 (95% CI = 0.78–0.93) and 0.69 (95%
CI = 0.17–0.50), respectively (HSROC shown in Figure 3c (red plot); AUC = 0.888).
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Figure 3. Studies evaluating SWE for the detection of prostate cancer with the histopathology of SB as a reference standard.
(a) Forest plot for per-sample level analysis. (b) Forest plot for per-patient level analysis. (c) Hierarchical summary
receiver operating characteristic (HSROC) curves (solid lines), for per-patient (red) and per-sample (blue) level analyses,
corresponding to the pooled sensitivity and false positive rate values, indicated by the solid red and blue circles, with 95%
confidence intervals about the pooled results shown by the dashed lines; the open triangles refer to individual studies.
Five studies, including 328 patients in total, evaluated SWE at the per-tissue level for
the diagnosis of prostate cancer with the histopathology of RP specimens as the reference
standard [2,3,11,12]. The sensitivities and specificities of individual studies ranged from
0.55 (95% CI = 0.49–0.61) to 0.89 (95% CI = 0.85–0.92), and 0.35 (95% CI = 0.24–0.49) to 0.97
(95% CI = 0.97–0.98), respectively. A threshold effect was not observed either on visual
interpretation of the forest plot (Figure 4a) or from assessment of the correlation between
sensitivity and the false-positive rate (Spearman coefficient = −0.50; p = 0.45; Figure 4b).
The pooled sensitivity and specificity of SWE for the diagnosis of prostate cancer with the
histopathology of RP specimens as the reference standard was 0.71 (95% CI = 0.55–0.83)
and 0.74 (95% CI 0.42–0.92), respectively (HSROC shown in Figure 4b, AUC = 0.771).
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Figure 4. Studies evaluating SWE at the per-tissue level for the detection of prostate cancer with histopathology of radical
prostatectomy (RP) specimens as the reference standard. (a) Forest plot and (b) HSROC curve corresponding to the pooled
sensitivity and false positive rate value indicated by the solid black circle, with 95% confidence intervals about the pooled
result shown by the dashed line; the open triangles refer to individual studies.
In meta-regression analysis (Table 3), among studies that used SB as the reference
with analysis performed at per-sample level, a prospective study design (compared to
retrospective) was significantly (p = 0.038) associated with a higher sensitivity (0.90 vs. 0.73),
whereas studies published between 2016–2020 (compared to in 2011–2015) had significantly
(p = 0.027) poorer specificity (0.69 vs. 0.88) for the detection of prostate cancer. Among
studies using whole-mount RP specimens as the reference, no factors were observed to
significantly affect heterogeneity.
According to the funnel plot (Figure 5), no evidence of significant asymmetry was
observed, and Egger’s test showed no statistical evidence of publication bias (p = 0.561).
Sub-group analysis revealed a lower pooled sensitivity (0.82 vs. 0.86) and specificity
(0.79 vs. 0.85) for studies evaluating SWE for t e detection of csPCa c mpared to overall
PCa with SB as the reference standard. In contrast, among studies using histopathology of
whole-mount RP specimens as the reference standard, pooled estimates for both sensitivity
(0.77 vs. 0.61) and specificity (0.84 vs. 0.53) were superior among studies evaluating SWE
for the detection of csPCa compared to overall PCa.
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Table 3. Summary of the meta-regression analysis of SWE for the detection of prostate cancer, with respect to the reference
histopathology standard. SB: systematic biopsy; RP: radical prostatectomy; csPCa: clinically significant prostate cancer.
Variable SB as Reference Whole-Mount RP Histopathology as Reference
Covariate No. ofStudies
Pooled
Sensitivity
(95% CI)
p-Value
Pooled
Specificity
(95% CI)
p-Value Number ofStudies
Pooled
Sensitivity
(95% CI)
p-Value
Pooled
Specificity
(95% CI)
p-
Value
Study design
Prospective 5 0.90(0.82–0.95) 0.038
0.87
(0.72–0.95) 0.487 5
0.71
(0.55–0.83) -
0.74
(0.42–0.92) -
Retrospective 4 0.73(0.51–0.88)
0.81
(0.68–0.89) 0 - -
csPCa
definition
used
Yes 2 0.82(0.74–0.88) 0.732
0.79
(0.43–0.94) 0.557 3
0.77
(0.53–0.91) 0.309
0.84
(0.42–0.97) 0.292
No/Unspecified 7 0.86(0.72–0.94)
0.85
(0.75–0.92) 2
0.62
(0.53–0.70)
0.53
(0.21–0.83)
SWE focus
region
Whole gland 6 0.81(0.67–0.90) 0.161
0.84
(0.73–0.91) 0.879 4
0.74
(0.54–0.87) 0.566
0.75
(0.34–0.94) 0.915
PZ only 3 0.94(0.74–0.99)
0.86
(0.56–0.96) 1
0.61
(0.50–0.72)
0.70
(0.64–0.77)
Year of
publication
2011–2015 6 0.88(0.73–0.93) 0.407
0.88
(0.83–0.92) 0.027 1
0.81
(0.74–0.87) 0.495
0.69
(0.62–0.75) 0.877
2016–2020 3 0.79(0.70–0.86)
0.69
(0.30–0.96) 4
0.68
(0.47–0.84)
0.75
(0.35–0.94)
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3. Discussion 
In this systematic review, the sensitivity and specificity of SWE for the detection of 
prostate cancer ranged from 0.71–0.87 and 0.69–0.85, respectively, depending on the level 
of analysis and the reference standard used. Studies using SB as the reference standard at 
the per‐sample and per‐participant level of analysis had a higher pooled sensitivity and 
specificity compared to studies using whole‐mount histopathology of RP specimens. As 
SWE has relatively lower accuracy in detecting and characterizing PCa in the TZ [39,40], 
this could account for the lower sensitivity and specificity when using whole‐mount his‐
topathology of  the RP specimens.  In contrast  to previous reviews  [11–13], we have re‐
ported separate pooled diagnostic estimates based on the reference standard utilised and 
the level of analysis performed, in order to provide a more reliable and informative esti‐
mate for the accuracy of SWE in diagnosing PCa.   
In a sub‐group analysis, studies that evaluated SWE for the detection of csPCa at the 
per‐sample level analysis using histopathology of whole‐mount RP specimens as the ref‐
Figure 5. Funnel plot to ass f i al ating S E for the detection of
prostate cancer at the sample level, with either SB or whole-mount histopathology of the RP specimen
as the reference standard.
3. Discus ion
In this systematic review, the sensitivity and specificity of SWE for the detection of
prostate cancer ranged from 0.71–0.87 and 0.69–0.85, respectively, depending on the level
of analysis and the reference standard used. Studies using SB as the reference standard at
the per-sample and per-participant level of analysis had a higher pooled sensitivity and
specificity compared to studies using whole-mount histopathology of RP specimens. As
SWE has relatively lower accuracy in detecting and characterizing PCa in the TZ [39,40],
this could account for the lower sensitivity and specificity when using whole-mount
histopathology of the RP specimens. In contrast to previous reviews [11–13], we have
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reported separate pooled diagnostic estimates based on the reference standard utilised
and the level of analysis performed, in order to provide a more reliable and informative
estimate for the accuracy of SWE in diagnosing PCa.
In a sub-group analysis, studies that evaluated SWE for the detection of csPCa at
the per-sample level analysis using histopathology of whole-mount RP specimens as the
reference standard had a higher sensitivity (0.77 vs. 0.62) and specificity (0.84 vs. 0.53)
compared to studies that detected all PCa. This superior sensitivity and specificity were
higher even than those obtained using SB as the reference standard for per-sample level
analysis. Significant study heterogeneity, together with more methodologically robust
contemporary studies adopting RP specimens as reference standard, may explain the
poorer pooled specificity observed among newer studies using SB as reference standard.
In a recently concluded meta-analysis, mpMRI had a sensitivity and specificity of
0.87 and 0.68, respectively, for the detection of all PCa in biopsy-naïve men [41]. These
estimates are comparable to the pooled diagnostic estimates for SWE, reported in this
review. For the detection of csPCa, we observed a pooled sensitivity and specificity of 0.77
and 0.84 from three studies that evaluated SWE using whole-mount histopathology of RP
specimens as the reference standard. This is similar to findings by Le et al., who reported a
sensitivity of 0.72 with mpMRI for the detection of tumours with Gleason score ≥ 7, using
an identical reference standard [42]. Several studies included in this review have compared
SWE with mpMRI for the detection of PCa. In a prospective study that included 78 men
with suspected PCa, Zhang et al. reported similar sensitivity (0.90 vs. 0.94) but superior
specificity (0.83 vs. 0.60) for SWE compared to mpMRI, respectively, for the detection of
PCa lower than T2 stage [10]. In a separate retrospective study, superior sensitivity (0.86
vs. 0.78) and specificity (0.92 vs. 0.62) for mpMRI compared to SWE for per-sample level
analysis was observed [9]. However, for per-participant level analysis, SWE had identified
10/15 positive prostates (clinically significant PZ lesions) that were negative on an mpMRI,
suggesting a potential role for SWE in combination with mpMRI.
Stiffness values for benign prostate glands, as reported in several studies, have been
significantly greater in the TZ than in the PZ [20,28]. Consequentially, higher SWE cut-off
values have been reported to optimally distinguish benign from malignant regions in the
TZ compared to the PZ. This difference may be due to a number of reasons. First, benign
prostatic hyperplasia nodules are ubiquitous in the heterogenous TZ (mixture of glandular
and stromal tissue), giving rise to increased stiffness. Second, greater transducer pressure
may be applied by the SWE operator when imaging the deeper TZ, artificially increasing
tissue stiffness due to the nonlinear mechanical behaviour of tissue [43]. In fact, in a study
evaluating SWE inter-operator reliability, the greatest agreement between operators was
observed with stiffness estimates from the base PZ, which, being comparatively easier
to visualise than the TZ, is less likely to be affected by differences in probe-induced
pressure [28]. Mannaerts et al. (study included in this review) reported a higher sensitivity
(0.65 vs. 0.61) and specificity (0.62 vs. 0.60) for the detection of PCa in the PZ compared to
TZ, defined by a Gleason score ≥3 + 4, with a tumour volume greater than 0.5 mL, extra-
prostatic extension, or pN1 stage [25]. This improved detection of PZ lesions compared to
TZ lesions was, however, not observed when only one of the described criteria for defining
csPCa was applied. Nonetheless, it is clear from the literature that prostatic region may
influence SWE accuracy. This was also observed in the sub-group analysis in this review,
with higher pooled sensitivity and specificity observed among studies imaging only the
PZ in contrast to the whole gland, with SB samples as the reference standard.
There are several limitations in this review. First, several studies included in the
review were published prior to the inception of a standardised SWE imaging protocol [39].
Furthermore, as some studies have reported diagnostic accuracy results with SWE as
part of a multiparametric ultrasound, it remains unclear whether variations in imaging
protocol or operator experience could have contributed to differences in accuracy. To
minimise the effect of these study-specific variations, we have performed meta-regression
analyses to assess for potential heterogeneity originating from the SWE focus region or the
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histopathological definition of PCa used. However, with the exception of the per-patient
evaluation of SWE for the detection of prostate cancer, with the histopathology of SB as
the reference standard (red curve and points in Figure 3c), the HSROC curves were a poor
fit to the sensitivity and false-positive rate values obtained from the included studies. As
for operator experience, inter-observer and intra-observer reliability with SWE have been
primarily evaluated in two studies (not included in this review) [28,29]. Although good
agreement between estimates for Young’s modulus have been observed in both studies,
significant variation was present, particularly between readings from the ventral regions of
the prostate gland. It remains to be investigated if separate threshold values for the various
regions (i.e., PZ and TZ) of the prostate gland may improve accuracy for detecting csPCa.
This systematic review highlights that SWE has good sensitivity (0.71–0.87) and
specificity (0.69–0.85) for the detection of all PCa and csPCa. A higher sensitivity and
specificity were observed in studies evaluating SWE for the detection of csPCa compared to
all PCa, using the histopathology of whole-mount RP specimens as the reference standard.
These results advocate for a potential role for SWE for the detection of csPCa and reducing
overtreatment of indolent PCa. To further elucidate the role of SWE, we recommend that
future studies should aim to derive optimal SWE cut-off values and prospectively utilise
standardised imaging protocols [39], in order to evaluate whether SWE could contribute
to improved stratification of patients for whom active surveillance, instead of immediate
radical or definitive management, is recommended.
This systematic review has updated the evidence and knowledge on SWE for the
detection PCa, and for the first time quantifies pooled diagnostic estimates of SWE for the
detection of csPCa. Its role for the diagnosis of csPCa in the context of novel ultrasound
techniques and the emerging “magnetic resonance pathway” need to be evaluated further.
In conclusion, SWE is an attractive strategy to improve detection of csPCa and reducing
overtreatment of indolent PCa.
4. Materials and Methods
The literature review for this systematic review was performed in accordance with
the Cochrane diagnostic test’s accuracy review guidelines. The search strategy involved
literature from the following computerized databases up to 31 March 2020: MEDLINE,
EMBASE, Cochrane Library, ClinicalTrials.gov, and CINAHL. To identify studies evaluating
the diagnostic accuracy of SWE for PCa, the following search terms and medical subject
heading (MeSH) phrases were incorporated into the search strategy: “Prostatic Neoplasms
[MeSH] OR Prostate” AND “Elasticity Imaging Techniques [MeSH] OR elastography”
AND “shear OR shearwave OR shear-wave”. The bibliographies of relevant studies and
previous reviews were evaluated to identify other studies eligible for inclusion in this
systematic review.
Inclusion of studies were based on the following criteria: (1) SWE was performed
to investigate prostate stiffness; (2) studies comparing the diagnostic accuracy of SWE
to reference the standard, based on either histopathologic assessment of SB or whole-
mount RP specimens. Studies with insufficient data to reconstruct 2 × 2 diagnostic tables,
reporting experimental laboratory data/animal studies, or classified as review articles,
conference abstracts, guidelines, editorials, or letters, were excluded.
Potential studies for inclusion in this review were independently identified by two
reviewers (T.A. and G.N.). In the case of disagreement regarding the suitability of select
studies for inclusion, a third reviewer was involved to resolve any disagreement between
primary extracting authors.
From the studies included for analysis, the following variables were extracted: author-
ship, publication year, country of origin, study design, patient demographics, reported
mean or median PSA level and prostate volume, reference pathology, SWE ultrasound
system utilized, and scanning parameters and level of analysis performed (patient- or
sample-level). Diagnostic performance data were collected to reconstruct 2 × 2 tables
from which the sensitivity and specificity of SWE for each included study was calculated.
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Studies that utilised a histopathological threshold of a Gleason score at least >6 for the
diagnosis of PCa were classified as evaluating SWE for the detection of csPCa.
The revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool
was used to evaluate the methodological quality of included studies independently by
two authors [44]. Disagreements between primary reviewers were discussed with a third
reviewer until a consensus was reached.
Studies evaluating SWE diagnostic performance for the detection of PCa were grouped
according to reference histopathology used (SB or whole-mount RP specimens) and type of
analysis performed (per-sample or per-patient level). Using a bivariate modelling approach
and hierarchical summary receiver operating characteristic (HSROC) calculation, pooled
sensitivity and the specificity of SWE for each group of studies were estimated [45].
A meta-regression analysis was performed to evaluate the following covariates (study
design, definition of prostate cancer, regions of prostate gland assessed by SWE, and year of
publication) as potential sources of heterogeneity affecting the diagnostic potential of SWE
for prostate cancer. Publication bias was assessed via the visual assessment of a conspicuity
funnel plot for symmetry and Egger’s regression test. Only studies evaluating SWE for
the diagnosis of prostate cancer using either SB or whole-mount RP histopathology as the
reference at the per-sample level were included for assessment for meta-regression and
publication bias analysis. A separate analysis for publication bias among studies evaluating
SWE at the participant level was not performed, due to the limited number of studies (<10).
RevMan 5.3 and the Mada and Metafor package on RStudio version 3.5.1 (RStudio, Inc.,
Boston, MA, USA) were used for all statistical analyses.
5. Conclusions
This systematic review has updated the evidence and knowledge on SWE for the
detection PCa, and for the first time quantifies pooled diagnostic estimates of SWE for the
detection of csPCa. Its role for the diagnosis of csPCa in the context of novel ultrasound
techniques and the emerging “MR pathway” need to be evaluated further. In conclusion,
SWE is an attractive strategy to improve detection of csPCa and reducing overtreatment of
indolent PCa.
Author Contributions: T.A.: writing—original draft, methodology, data curation, software, formal
analysis; C.W.: data curation; J.C.B.: writing—review and editing, Validation; R.G.B.; writing—review
and editing; G.N.: conceptualization, methodology, writing—review and editing, supervision. All
authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available within this article.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Abraham, N.E.; Mendhiratta, N.; Taneja, S.S. Patterns of repeat prostate biopsy in contemporary clinical practice. J. Urol. 2015,
193, 1178–1184. Available online: http://www.ncbi.nlm.nih.gov/pubmed/25444971 (accessed on 5 August 2020). [CrossRef]
2. Ahmed, H.U.; El-Shater Bosaily, A.; Brown, L.C.; Gabe, R.; Kaplan, R.; Parmar, M.K.; Collaco-Moraes, Y.; Ward, K.; Hindley,
R.G.; Freeman, A.; et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired
validating confirmatory study. Lancet 2017, 389, 815–822. [CrossRef]
3. Serefoglu, E.C.; Altinova, S.; Ugras, N.S.; Akincioglu, E.; Asil, E.; Balbay, M.D. How reliable is 12-core prostate biopsy procedure
in the detection of prostate cancer? J. Can. Urol. Assoc. 2013, 7, E293–E298. Available online: http://www.ncbi.nlm.nih.gov/
pubmed/22398204 (accessed on 5 August 2020). [CrossRef]
4. EAU Guidelines: Prostate Cancer|Uroweb. Available online: https://uroweb.org/guideline/prostate-cancer/#note_193
(accessed on 5 August 2020).
Cancers 2021, 13, 122 13 of 15
5. Richenberg, J.; Løgager, V.; Panebianco, V.; Rouviere, O.; Villeirs, G.; Schoots, I.G. The primacy of multiparametric MRI in men with
suspected prostate cancer. Eur. Radiol. 2019, 29, 6940–6952. Available online: http://www.ncbi.nlm.nih.gov/pubmed/31172275
(accessed on 5 August 2020). [CrossRef]
6. Sonn, G.A.; Fan, R.E.; Ghanouni, P.; Wang, N.N.; Brooks, J.D.; Loening, A.M.; Daniel, B.L.; To’o, K.J.; Thong, A.E.; Leppert, J.T.
Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. Eur. Urol. Focus 2019, 5, 592–599.
Available online: http://www.ncbi.nlm.nih.gov/pubmed/29226826 (accessed on 5 August 2020). [CrossRef] [PubMed]
7. Beerlage, H.P.; Aarnink, R.G.; Ruijter, E.; Witjes, J.A.; Wijkstra, H.; Van De Kaa, C.A.; Debruyne, F.J.; De La Rosette, J.J.M.C.H.
Correlation of transrectal ultrasound, computer analysis of transrectal ultrasound and histopathology of radical prostatectomy
specimen. Prostate Cancer Prostatic Dis. 2001, 4, 56–62. [CrossRef] [PubMed]
8. Bercoff, J.; Tanter, M.; Fink, M. Supersonic shear imaging: A new technique for soft tissue elasticity mapping. IEEE Trans. Ultrason.
Ferroelectr. Freq. Control 2004, 51, 396–409. [CrossRef] [PubMed]
9. Xiang, L.H.; Fang, Y.; Wan, J.; Xu, G.; Yao, M.H.; Ding, S.S.; Liu, H.; Wu, R. Shear-wave elastography: Role in clinically significant
prostate cancer with false-negative magnetic resonance imaging. Eur. Radiol. 2019, 29, 6682–6689. [CrossRef] [PubMed]
10. Zhang, M.; Tang, J.; Luo, Y.; Wang, Y.; Wu, M.; Memmott, B.; Gao, J. Diagnostic performance of multiparametric transrectal
ultrasound in localized prostate cancer: A comparative study with magnetic resonance imaging. J. Ultrasound Med. 2019, 38,
1823–1830. Available online: http://www.ncbi.nlm.nih.gov/pubmed/30561768 (accessed on 5 August 2020). [CrossRef]
11. Sang, L.; Wang, X.M.; Xu, D.Y.; Cai, Y.F. Accuracy of shear wave elastography for the diagnosis of prostate cancer: A meta-
analysis. Sci. Rep. 2017, 7, 1949. Available online: http://www.ncbi.nlm.nih.gov/pubmed/28512326 (accessed on 5 August 2020).
[CrossRef]
12. Woo, S.; Suh, C.H.; Kim, S.Y.; Cho, J.Y.; Kim, S.H. Shear-wave elastography for detection of prostate cancer: A systematic review
and diagnostic meta-analysis. Am. J. Roentgenol. 2017, 209, 806–814. Available online: http://www.ncbi.nlm.nih.gov/pubmed/
28796546 (accessed on 5 August 2020). [CrossRef] [PubMed]
13. Yang, Y.; Zhao, X.; Shi, J.; Huang, Y. Value of shear wave elastography for diagnosis of primary prostate cancer: A systematic
review and meta-analysis. Med Ultrason. Soc. Romana Ultrason. Med. Biol. 2019, 21, 382–388. Available online: http://www.ncbi.
nlm.nih.gov/pubmed/31765445 (accessed on 5 August 2020). [CrossRef] [PubMed]
14. Zheng, X.; Ji, P.; Mao, H.; Hu, J. A comparison of virtual touch tissue quantification and digital rectal examination for discrimina-
tion between prostate cancer and benign prostatic hyperplasia. Radiol. Oncol. 2012, 46, 69–74. [CrossRef] [PubMed]
15. Barr, R.G.; Memo, R.; Schaub, C.R. Shear wave ultrasound elastography of the prostate: Initial results. Ultrasound Q. 2012, 28,
13–20. Available online: http://www.ncbi.nlm.nih.gov/pubmed/22357224 (accessed on 5 August 2020). [CrossRef] [PubMed]
16. Woo, S.; Kim, S.Y.; Cho, J.Y.; Kim, S.H. Shear wave elastography for detection of prostate cancer: A preliminary study. Korean
J. Radiol. 2014, 15, 346–355. Available online: http://www.ncbi.nlm.nih.gov/pubmed/24843239 (accessed on 5 August 2020).
[CrossRef]
17. Boehm, K.; Salomon, G.; Beyer, B.; Schiffmann, J.; Simonis, K.; Graefen, M.; Budaeus, L. Shear wave elastography for localization
of prostate cancer lesions and assessment of elasticity thresholds: Implications for targeted biopsies and active surveillance
protocols. J. Urol. 2015, 193, 794–800. Available online: http://www.ncbi.nlm.nih.gov/pubmed/25264337 (accessed on 5 August
2020). [CrossRef]
18. Boehm, K.; Budäus, L.; Tennstedt, P.; Beyer, B.; Schiffmann, J.; Larcher, A.; Simonis, K.; Graefen, M.; Beyersdorff, D.; Salomon, G.
Prediction of Significant Prostate Cancer at Prostate Biopsy and Per Core Detection Rate of Targeted and Systematic Biopsies
Using Real-Time Shear Wave Elastography. Urol. Int. 2015, 95, 189–196. Available online: https://www.karger.com/Article/
FullText/431233 (accessed on 5 August 2020). [CrossRef]
19. Correas, J.M.; Tissier, A.M.; Khairoune, A.; Vassiliu, V.; Méjean, A.; Hélénon, O.; Memo, R.; Barr, R.G. Prostate cancer: Diagnostic
performance of real-time shear-wave elastography. Radiology 2015, 275, 280–289. Available online: http://www.ncbi.nlm.nih.
gov/pubmed/25599156 (accessed on 5 August 2020). [CrossRef]
20. Rouvière, O.; Melodelima, C.; Dinh, A.H.; Bratan, F.; Pagnoux, G.; Sanzalone, T.; Crouzet, S.; Colombel, M.; Mège-Lechevallier, F.;
Souchon, R. Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: A preliminary study. Eur.
Radiol. 2017, 27, 1858–1866. Available online: http://www.ncbi.nlm.nih.gov/pubmed/27553936 (accessed on 5 August 2020).
21. Ahmad, S.; Cao, R.; Varghese, T.; Bidaut, L.; Nabi, G. Transrectal quantitative shear wave elastography in the detection and
characterisation of prostate cancer. Surg. Endosc. 2013, 27, 3280–3287. [CrossRef]
22. Zhang, M.; Wang, P.; Yin, B.; Fei, X.; Xu, X.; Song, Y. Transrectal shear wave elastography combined with transition zone biopsy
for detecting prostate cancer. Zhonghua Nan Ke Xue 2015, 21, 610–614. Available online: http://www.ncbi.nlm.nih.gov/pubmed/
26333222 (accessed on 5 August 2020). [PubMed]
23. Porsch, M.; Görner, C.; Wendler, J.J.; Liehr, U.B.; Lux, A.; Siedentopf, S.; Schostak, M.; Pech, M. Inability of shear-wave
elastography to distinguish malignant from benign prostate tissue—A comparison of biopsy, whole-mount sectioning and
shear-wave elastography. J. Ultrason. 2016, 16, 348–358. [CrossRef] [PubMed]
24. Wei, C.; Li, C.; Szewczyk-Bieda, M.; Upreti, D.; Lang, S.; Huang, Z.; Nabi, G. Performance Characteristics of Transrectal Shear
Wave Elastography Imaging in the Evaluation of Clinically Localized Prostate Cancer: A Prospective Study. J. Urol. 2018, 200,
549–558. Available online: http://www.ncbi.nlm.nih.gov/pubmed/29605444 (accessed on 5 August 2020). [CrossRef] [PubMed]
Cancers 2021, 13, 122 14 of 15
25. Mannaerts, C.K.; Wildeboer, R.R.; Remmers, S.; van Kollenburg, R.A.; Kajtazovic, A.; Hagemann, J.; Postema, A.W.; van Sloun,
R.J.; JRoobol, M.; Tilki, D.; et al. Multiparametric Ultrasound for Prostate Cancer Detection and Localization: Correlation of
B-mode, Shear Wave Elastography and Contrast Enhanced Ultrasound with Radical Prostatectomy Specimens. J. Urol. 2019, 202,
1166–1173. Available online: http://www.ncbi.nlm.nih.gov/pubmed/31246546 (accessed on 5 August 2020). [CrossRef]
26. Ji, Y.; Ruan, L.; Ren, W.; Dun, G.; Liu, J.; Zhang, Y.; Wan, Q. Stiffness of prostate gland measured by transrectal real-time shear
wave elastography for detection of prostate cancer: A feasibility study. Br. J. Radiol. 2019, 92, 20180970. Available online:
http://www.ncbi.nlm.nih.gov/pubmed/30875242 (accessed on 5 August 2020). [CrossRef]
27. Fu, S.; Tang, Y.; Tan, S.; Zhao, Y.; Cui, L. Diagnostic Value of Transrectal Shear Wave Elastography for Prostate Cancer Detection
in Peripheral Zone: Comparison with MRI. J. Endourol. 2020. [CrossRef]
28. Harvey, H.; Morgan, V.; Fromageau, J.; O’Shea, T.; Bamber, J.; de Souza, N.M. Ultrasound Shear Wave Elastography of the Normal
Prostate: Interobserver Reproducibility and Comparison with Functional Magnetic Resonance Tissue Characteristics. Ultrason.
Imaging 2018, 40, 158–170. Available online: http://www.ncbi.nlm.nih.gov/pubmed/29353529 (accessed on 5 August 2020).
[CrossRef]
29. Woo, S.; Kim, S.Y.; Lee, M.S.; Cho, J.Y.; Kim, S.H. Shear wave elastography assessment in the prostate: An intraobserver
reproducibility study. Clin. Imaging 2015, 39, 484–487. Available online: http://www.ncbi.nlm.nih.gov/pubmed/25481218
(accessed on 5 August 2020). [CrossRef]
30. Wildeboer, R.R.; Mannaerts, C.K.; van Sloun, R.J.; Budäus, L.; Tilki, D.; Wijkstra, H.; Salomon, G.; Mischi, M. Automated
multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound
radiomics. Eur. Radiol. 2020, 30, 806–815. [CrossRef]
31. Wei, C.; Zhang, Y.; Malik, H.; Zhang, X.; Alqahtani, S.; Upreti, D.; Szewczyk-Bieda, M.; Lang, S.; Nabi, G. Prediction of
Postprostatectomy Biochemical Recurrence Using Quantitative Ultrasound Shear Wave Elastography Imaging. Front. Oncol.
2019, 9, 572. Available online: http://www.ncbi.nlm.nih.gov/pubmed/31338325 (accessed on 5 August 2020). [CrossRef]
32. Zheng, X.Z.; Ji, P.; Mao, H.W.; Zhang, X.Y.; Xia, E.H.; Chen, X.F. A novel approach to assessing changes in prostate stiffness with
age using Virtual touch tissue quantification. J. Ultrasound Med. 2011, 30, 387–390. Available online: http://www.ncbi.nlm.nih.
gov/pubmed/21357561 (accessed on 5 August 2020). [CrossRef] [PubMed]
33. Shoji, S.; Hashimoto, A.; Nakamura, T.; Hiraiwa, S.; Sato, H.; Sato, Y.; Tajiri, T.; Miyajima, A. Novel application of three-
dimensional shear wave elastography in the detection of clinically significant prostate cancer. Biomed. Rep. 2018, 8, 373–377.
Available online: http://www.ncbi.nlm.nih.gov/pubmed/29541458 (accessed on 5 August 2020). [CrossRef] [PubMed]
34. Wei, C.; Szewczyk-Bieda, M.; Nibblok, P.; Brown, E.; Lang, S.; Nabi, G. Quantitative transrectal shear wave elastography
undergoing salvage extraperitoneal laparoscopic radical prostatectomy following failed radiotherapy. Surg. Endosc. 2018, 32,
4552–4561. [CrossRef] [PubMed]
35. Glybochko, P.V.; Alyaev, Y.G.; Amosov, A.V.; Krupinov, G.E.; Ganzha, T.M.; Vorobev, A.V.; Lumpov, I.S.; Semendyaev, R.I. Prostate
cancer detection by assessing stiffness of different tissues using shear wave ultrasound elastog-raphy. Urologiia 2016, 3, 56–61.
Available online: http://www.ncbi.nlm.nih.gov/pubmed/28247631 (accessed on 5 August 2020).
36. Su, R.; Xu, G.; Xiang, L.; Ding, S.; Wu, R. A Novel Scoring System for Prediction of Prostate Cancer Based on Shear Wave
Elastography and Clinical Parameters. Urology 2018, 121, 112–117. Available online: http://www.ncbi.nlm.nih.gov/pubmed/30
171925 (accessed on 5 August 2020). [CrossRef]
37. Wu, F.; Zhang, M.B.; Wang, Y.R.; Yang, Y.Y.; Li, Y.Y. Application Value of Transrectal Shear Wave Elastography Mode Combined
with Elastic Modulus in the Diagnosis of Prostate Cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2020, 42, 73–79. Available online:
http://www.ncbi.nlm.nih.gov/pubmed/32131943 (accessed on 5 August 2020).
38. Shear, Q.B. Real time two-dimensional Prostate, wave elastography in diagnosis of prostate cancer. Pract Oncol. 2017, 23, 454–457.
39. Barr, R.G.; Cosgrove, D.; Brock, M.; Cantisani, V.; Correas, J.M.; Postema, A.W.; Salomon, G.; Tsutsumi, M.; Xu, H.X.; Dietrich, C.F.
Wfumb Guidelines and Recommendations On The Clinical Use Of Ultrasound Elastography: Part 5. Prostate. Ultrasound Med.
Biol. 2017. [CrossRef]
40. Correas, J.M.; Halpern, E.J.; Barr, R.G.; Ghai, S.; Walz, J.; Bodard, S.; Dariane, C.; de la Rosette, J. Advanced ultrasound in the
diagnosis of prostate cancer. World J. Urol. 2020, 1–16. [CrossRef]
41. Zhen, L.; Liu, X.; Yegang, C.; Yongjiao, Y.; Yawei, X.; Jiaqi, K.; Xianhao, W.; Yuxuan, S.; Rui, H.; Wei, Z.; et al. Accuracy of
multiparametric magnetic resonance imaging for diagnosing prostate Cancer: A systematic review and meta-analysis. BMC
Cancer. 2019, 19. [CrossRef]
42. Le, J.D.; Tan, N.; Shkolyar, E.; Lu, D.Y.; Kwan, L.; Marks, L.S.; Huang, J.; Margolis, D.J.; Raman, S.S.; Reiter, R.E. Multifocality and
prostate cancer detection by multiparametric magnetic resonance imaging: Correlation with whole-mount histopathology. Eur.
Urol. 2015, 67, 569–576. [CrossRef]
43. Bamber, J.; Cosgrove, D.; Dietrich, C.F.; Fromageau, J.; Bojunga, J.; Calliada, F.; Cantisani, V.; Correas, J.-M.; D’Onofrio, M.;
Drakonaki, E.E.; et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastographypart 1: Basic
principles and technology. Ultraschall Med. 2013, 34, 169–184. Available online: https://pubmed.ncbi.nlm.nih.gov/23558397/
(accessed on 5 August 2020).
Cancers 2021, 13, 122 15 of 15
44. Whiting, P.F.; Rutjes, A.W.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.; Sterne, J.A.; Bossuyt, P.M.
QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann. Intern. Med. 2011, 155, 529.
Available online: http://www.ncbi.nlm.nih.gov/pubmed/22007046 (accessed on 5 August 2020). [CrossRef]
45. Doebler, P.; Holling, H. Meta-Analysis of Diagnostic Accuracy with mada. Available online: http://r-forge.r-project.org/projects/
mada/ (accessed on 5 August 2020).
